Product Details: Number of Reactions(Preps)/Kit : 96 Wells Brand : InBios Sample Material : Serum Incubation Time: 60+60+60+5+10+1 Storage 2-8 C Cat No : DDMS-1 The DENV DetectTM IgM Capture ELISA is for the qualitative detection of IgM antibodies to DENV recombinant antigens in serum for the presumptive clinical laboratory diagnosis of Dengue virus infection. The assay is intended for use only in patients with clinical symptoms consistent with either dengue fever or dengue hemorrhagic fever. The complete kit includes one 96 well strippable plate with all necessary reagents and controls. 1st Assay to Receive FDA Clearance. Performance thoroughly evaluated with clinically confirmed cases of dengue 1-4 serotypes. Excellent positive and negative agreement with WHO reference panel (>90%). Improves accuracy by monitoring background reactivity with a normal cell antigen. Employs a simple, one step ratio method of interpretation. CE Marked.
Covd-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid phase immunochromatographic assay for the rapid, qualitative and dierential detection of IgG and IgM antibodies to 2019 Novel Corona Virus in human whole blood, serum or plasma. Specification.jpg Product: Rapid Diagnostic Test Kit Item: Corona Virus Test Kit Specimen: Whole Blood/Serum/Plasma Format: Strip/Cassette Port of Loading: Shanghai OEM and ODM: OEM/ODM Welcome Shipping: By UPS, FEDEX, DHL, TNT, by air or by sea MOQ for Private label: Low MOQ 1600 boxes, Please contact us. Note: Store this product in a cool and dry place, avoid direct sunlight, stay away from places that children can contact, and avoid eye contact. If you have allergies to this product, please stop using and consult a doctor. COVID-19 Corona Virus Rapid Test Kit11.pngCOVID-19 Corona Virus Rapid Test Kit12.png
Vannin Healthcare offers several effective COVID-19 tests: SGTi-flex COVID-19 IgM/IgG (25 tests per kit) STANDARD Q COVID-19 IgM/IgG Duo Test (40 tests per kit) Anti-SARS-CoV-2 Rapid Test (50 tests per kit) General Features Can detect and differentiate between IgM and IgG antibodies Convenient: no additional equipment necessary Extremely fast: results in 10-15 minutes Point-of-care testing Allow rapid decision-making in high-stakes situations Why our tests Certified: CE-IVD marked, FDA-cleared, ISO 13485, Korea GMP-certified Reliable: high clinical specificity and selectivity Easy to interpret Can detect antibodies even in asymptomatic patients Vannin Healthcare Global offers various diagnostic and serology tests for identifying the presence of Severe Acute Respiratory Syndrome Coronavirus2 (SARS-CoV-2). SARS-CoV-2 is the virus that causes COVID-19 which means that its presence could indicate that a person has been infected. There are two types of tests currently used to determine the presence of the virus: Molecular diagnostic tests or viral tests (Swab tests) Antibody serology tests (Blood tests) Vannin Healthcare Globalâ??s Serology Tests To find out whether antibodies are present in an obtained sample (whole blood, plasma, or serum), serology tests are used. The presence of antibodies could indicate a past infection. And depending on the type of the immunoglobulins present, it could also determine the approximate time when the infection occurred. After fighting a coronavirus, our bodies are likely to produce two classes of antibodies: IgM and IgG. In the case of SARS-CoV-2, both IgM and IgG are most likely to occur simultaneously within two to three weeks after a personâ??s been infected. For a firmer diagnosis, Vannin Healthcare Global offers serology tests that check for both IgM and IgG antibodies. Can detect and differentiate between IgM and IgG antibodies Differentiating between the antibodies is crucial when it comes to providing proper medical advice to your patients. The appearance of IgM antibodies is the initial response of the organism fighting to suppress the virus. These antibodies could indicate that the patient is still infectious, and advising patients to self-isolate is the appropriate course of action. IgG antibodies can be detected in the blood sample usually within7-10 days after the onset of infection. If a patient has IgG antibodies, and no IgM antibodies, they have developed a temporary immunity to COVID-19. No additional equipment necessary The test design makes it a perfect choice for remote areas without access to fully-equipped laboratories. Simply obtain a blood sample from a patient, and add 10�µl into the appropriate place on the testing cassette along with three drops (90�µl) of the buffer. The results will appear in 10-15 minutes. Point-of-care testing Being easy-to-interpret and fast, it is ideal for rapid decision-making in the ICU or during a consultation with a patient. In medical disaste
Product Details: Number of Reactions(Preps)/Kit ; 96 Wells Brand : InBios Format : Immunocapture Specimen : Serum Cat No : ZKM2-1 The ZIKV Detect 2.0 IgM Capture ELISA is intended for the qualitative detection of Zika virus IgM antibodies in human sera for the presumptive clinical laboratory diagnosis of Zika virus infection. The assay is intended for use only in patients with clinical signs and symptoms consistent with Zika virus infection, and/or CDC Zika virus epidemiological criteria (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated). Assay results are for the presumptive detection of IgM antibodies to Zika virus (ZIKV). Positive results must be confirmed by following the latest CDC guidelines for the diagnosis of Zika virus infection. Results of this test are intended to be used in conjunction with clinical observations, patient history, epidemiological information, and other laboratory evidence to make patient management decisions. Zika IgM levels are variable over the course of the infection and may be detectable near day four post onset of symptoms and persist up to approximately 12 weeks following initial infection. Negative results may be seen in specimens collected before day four post onset of symptoms or after the window of detectable IgM closes, and therefore do not preclude the possibility of Zika virus infection, past or present. 1st Commercial serology kit to receive FDA Marketing Authorization CE Marked Differentiates Zika IgM positive patients from those infected with other flaviviruses such as West Nile or Dengue Sensitivity: >90% Specificity: >96% Results in 4 hours Tests up to 28 unknown specimens.
GENEDIA W COVID-19 IgM/IgG device is a chromatographic immunoassay kit for the rapid and differential detection of immunoglobulin M (lgM) and immunoglobulin G (IgG) against COVID-19 using serum, plasma and whole blood. Allow wider testing with fast test time (10 minutes) Perform directly at the point of care High capacity to meet the most urgent medical and public health needs Package Unit : 20 Tests/Kit Expiration Date : 24 Months
Product Details: Number of Reactions(Preps)/Kit : 96 Wells Brand : InBios Sample Material : Serum Format : Antigen Detection Incubation Time : 60+30+20+1 Cat No : DNS1-1 The DENV DetectTM NS1 ELISA is for the early detection of Dengue virus (DENV) NS1 antigen in human serum. This test is for the presumptive clinical laboratory diagnosis of Dengue virus infection. This assay is intended for use in patients with clinical symptoms consistent with either dengue fever or dengue hemorrhagic fever. Samples collected from patients within seven (7) days after the onset of clinical symptoms should be evaluated with this assay (day 0 â?? day 7). Negative results obtained with this test do not preclude the diagnosis of dengue and should not be used as the sole basis for treatment or other patient management decision. This assay is not FDA cleared or approved for testing blood or plasma donors. The complete kit includes one 96 well strippable plate with all necessary reagents and controls. FDA Cleared & CE Marked Early NS1 antigen detection (within first 7 days onset of symptoms) Helps differentiate dengue from other flaviviruses that may cross react with dengue antibodies but not with the antigen High Sensitivity & Specificity: 86.6% PPA & 97.8% NPA with prospectively collected positive and negative confirmed clinical specimens Kit can be performed in parallel with InBiosâ?? FDA Cleared dengue IgM ELISA for presumptive diagnosis of acute or convalescent stage dengue virus.
COVID-19 IgM/IgG Antibody Detection Kit (Colloidal Gold Immunochromatography) is suitable for the qualitative detection of COVID-19 by detecting SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. Common signs of infection with SARS-CoV-2 include respiratory symptoms, fever, cough, shortness of breath, and dyspnea. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death. SARS-CoV-2 can be excreted through respiratory secretions or transmitted through oral fluids, sneezing, physical contact, and through air droplets
Product Details: Number of Reactions(Preps)/Kit : 96 wells Brand : Abbott Usage/Application : Hospital Sample Material : Serum CAT No : 11EK10 The Panbio Dengue IgM Capture ELISA is used to detect IgM antibodies to dengue antigen in serum as an aid to clinical laboratory diagnosis of patients with clinical symptoms consistent with dengue fever. The Panbio. Dengue IgM Capture ELISA should be used in conjunction with other dengue serology.
Product Details: Brand : Abbott Package type : Microplate Pack size : 96wells/Kit Specimen : Serum Description : Dengue IgM Capture ELISA Cat.No. : 11EK20 Bioline DENGUE IgM CAPTURE ELISA In primary infection with the dengue virus, IgM antibody becomes detectable about five days after disease onset, when circulating virus declines in the blood. IgM level rises quickly to peak at about 2 weeks and declines to undetectable levels after 2-3 months In secondary infections, IgM response is typically at a lower level compared to that in a primary infection. Early diagnosis of dengue infection (especially in primary dengue infection) High accuracy with all dengue serotypes (DEN1,2,3, and 4) Simple and easy to use: All necessary reagents included in the kit Shelf life and storage temperature: 18 months from the date of manufacturing at 2-8 C Included in the WHO Bulk Procurement Scheme Performance: Sensitivity 96.4 %, Specificity 98.9 % (vs. HAI test).
High accuracy High quality, with CE certificate. 10 tests per box
Product Details: Number of Reactions(Preps)/Kit : 96 Wells Brand : InBios Sample Material : Serum Format : Immunocapture Incubation Time : 30+30+30+10 Cat No : CHKM-R The CHIKjj Detect IgM ELISA is designed for the qualitative detection of IgM antibodies present in human serum targeting Chikungunya virus E2/E1 proteins. This test is not intended to screen blood or blood components. This test is for research use only. Not for use in diagnostic procedures. The complete kit includes one 96 well strippable plate with all necessary reagents and controls. Key Features : InBios chikungunya kits have been developed using a novel technology1 that outperforms traditional antigen preparations, resulting in highly sensitive detection of recent and past CHIKV infection. Excellent results in CDC evaluation of commercially available chikungunya IgM assays. Ordering: Cat No CHKM-R Formet Immunocapture Quantity 96 wells/Plate Incubation Time 30 + 30 + 5 + 10 Sample Type Serum Storage 2-8 Shelf Life 12 months
Product Details: Number of Reactions(Preps)/Kit : 50 Brand : SD ICMR Approved : Yes Result Time (Rapid Kits) : 15 min Sample Type : Oral & Nasal Swab STANDARD E Dengue IgM ELISA analyzes IgM antibodies specific to Dengue virus in serum and plasma using enzyme linked immunosorbent assay.
Product Details: Number of Reactions(Preps)/Kit : 96 Wells Brand : InBios Sample Material : Serum Format : ELISA Incubation Time : 30 + 30 + 5 + 10 + 1 Cat No : STMS-R The Scrub Typhus Detect IgM ELISA for exposure to Orientia tsutsugamushi (OT; formerly Rickettsia) is an ELISA system for the detection of IgM antibodies in human serum to OT-derived recombinant antigen. This test is for research use only. Not for use in diagnostic procedures. The complete kit includes one 96 well strippable plate with all necessary reagents and controls.
The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device utilizes lateral flow technology that is used for the qualitative, differential detection of both anti-SARS-CoV-2 IgM and IgG antibodies. In general, antibodies can be detected 1-3 weeks after infection. This test is intended to screen patients for COVID-19. Combining RNA and Antibody tests can significantly raise the sensitivity for detecting COVID-19 in infected individuals. This test has been authorized by the FDA under a EUA for professional use CLIA and CLIA WAIVED for Point Of Care. This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. This product is intended for professional use and not for home use. FACT SHEET FOR HEALTHCARE PROVIDERS This test has been authorized by the FDA under a EUA for use by authorized CLIA laboratories. This device is CLIA waived for point of care use for fingerstick whole blood specimens only. The user should be trained in the procedure. Wear appropriate protective attire for your safety when handling patient samples. This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. There should be a blue line in the control region (next to ) before testing, discard the device if there is no blue line.
The Elisa Reader/Microplate Reader is a vital medical device for hospitals, facilitating precise diagnostics and research. This sophisticated equipment efficiently reads microplate assays, delivering accurate results for a wide range of tests. With its user-friendly interface and versatile software, it enables seamless data analysis. Its optical system ensures high sensitivity and a broad detection range, making it ideal for various assays. The compact design saves valuable lab space, while the robust construction ensures longevity. This indispensable tool is crucial for diagnosing diseases, monitoring treatment efficacy, and advancing medical research, making it an indispensable asset for any hospital's laboratory.
Compact, stylized ip mini-dome ideal for indoor retail, casinos, public buildings/ 2mp resolution (1600 x 1200) to capture large indoor spaces with fewer cameras/ true day/night ir cut filte/ flexible control: 350° pan, +85° to -35° tilt, 3x optical zoom and 4x digital zoom/ built-in sd card slot for video recording at the camera (sd/sdhc cards)/ quad streaming mpeg4 and motion jpeg/ two-way audio with built-in mic/ cable management/ tamper and motion detection/
Uncut Sheet Leishmania IgG/IgM Rapid Test Specimen:Whole Blood/ Serum/ Plasma INTENDED USE The Leishmania IgG/IgM Rapid Test is a lateral flow immunoassay for the qualitative detection of antibodies including IgG and IgM to the subspecies of the Leishmania donovani (L. donovani), the Visceral leishmaniasis causative protozoans in human serum or plasma. This test is intended to be used as a screening test and as an aid in the diagnosis of the disease of Visceral leishmaniasis. Any reactive specimen with the Leishmania IgG/IgM Rapid Test must be confirmed with alternative testing method(s). SUMMARY AND EXPLANATION OF THE TEST Visceral leishmaniasis, or Kala-azar, is a disseminated infection caused by several subspecies of the L. donovani. The disease is estimated by the World Health Organization (WHO) to affect approximately 12 million people in 88 countries1. It is transmitted to humans by bites of the Phlebotomus sandflies, which acquire infection from feeding on infected animals. Though it is a disease for poor countries, in Southern Europe, it has become the leading opportunistic infection in AIDS patients2-3. Identification of L. donovani organism from the blood, bone marrow, liver, lymph nodes or the spleen provides a definite means of diagnosis. However, these test methods are limited by the sampling method and the special instrument requirement. Serological detection of anti-L. donovani Ab is found to be an excellent marker for the infection of Visceral leishmaniasis. Tests used in clinic include: ELISA, fluorescent antibody and direct agglutination tests4-5. Recently, utilization of L. donovani specific protein in the test has improved the sensitivity and specificity dramatically6-7. The Leishmania IgG/IgM Rapid Test is a recombinant protein based serological test, which detects antibodies including IgG, IgM and IgA to the L. Donovani. This test provides a reliable result within 10 minutes without any instrumentation requirements.
Intended Use The One Step HAV IgG/IgM Test is a rapid chromatographic immunoassay for the qualitative detection of antibodies (IgG and IgM) to Hepatitis A Virus (HAV) in Whole Blood /Serum / Plasma to aid in the diagnosis of Hepatitis A Virus. Summary Hepatitis A is an acute, usually self-limiting disease of the liver caused by hepatitis A virus (HAV). HAV is transmitted from person to person, primarily by the faecal-oral route. The incidence of hepatitis A is closely related to socioeconomic development, and seroepidemiological studies show that prevalence of anti-HAV antibodies in the general population varies from 15% to close to 100% in different parts of the world. One step HAV IgG/IgM Test is a simple, visual qualitative test that detects Hepatitis A Virus antibodies in human Whole Blood /Serum / Plasma. The test is based on immunochromatography and can give a result within 15 minutes. Principle The One Step HAV IgG/IgM Test is a qualitative membrane strip based immunoassay for the detection of Hepatitis A Virus antibodies (IgG and IgM) in Whole Blood /Serum / Plasma. The test device consists of: 1) a burgundy colored conjugate pad containing HAV recombinant envelope antigens conjugated with Colloid gold (HAV conjugates) and rabbit IgG-gold conjugates,2) a nitrocellulose membrane strip containing two test bands (T1 and T2 bands) and a control band (C band). The T1 band is pre-coated with the antibody for the detection of IgM anti-HAV, T2 band is coated with antibody for the detection of IgG anti-HAV, and the C band is pre-coated with goat anti rabbit IgG. When an adequate volume of test specimen is dispensed into the sample well of the test cassette, the specimen migrates by capillary action across the cassette. IgG anti-HAV, if present in the specimen, will bind to the HAV conjugates. The immunocomplex is then captured by the reagent pre-coated on the T2 band, forming a burgundy colored T2 band, indicating a HAV IgG positive test result and suggesting a recent or repeat infection. IgM anti-HAV if present in the specimen will bind to the HAV conjugates. The immunocomplex is then captured by the reagent coated on the T1 band, forming a burgundy colored T1 band, indicating a HAV IgM positive test result and suggesting a fresh infection. Absence of any T bands (T1 and T2) suggests a negative result. The test contains an internal control (C band) which should exhibit a burgundy colored band of the immunocomplex of goat anti rabbit IgG/rabbit IgG-gold conjugate regardless of the color development on any of the T bands. Otherwise, the test result is invalid and the specimen must be retested with another device. Storage and Stability Store as packaged in the sealed pouch at room temperature or refrigerated (4-30â?? or 40-86â??). The test device is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use.